Bact erial infections cause significant mortality and morbidity worldwide despite the availability of antibiotics. In the United States alone, approximately 2 million patients develop a hospitalacquired infection each year. Klebsiella pneumoniae is a gramnegative, rod-shaped organism that is the fifth most prevalent nosocomial bacterial pathogen in the United States for infections associated with the urinary tract, ventilator associated pneumonia, and central line-associated bacteremia and accounts for 6% of all nosocomial bacterial disease (1, 2) . The conventional diagnosis of K. pneumoniae infection is derived from cultures of samples obtained from the site of suspected infection, which can take several days and may not provide reliable information since blood cultures can have high contamination rates. There are other clinical methods to identify infection, such as monitoring of body temperature, white blood cell count, erythrocyte sedimentation rate, and cytokine reactions, but none of these is a specific response to infection or able to differentiate bacterial infection from inflammation (3) . In addition, the emergence of K. pneumoniae resistance to antimicrobial drug is well documented (4) .
Noninvasive imaging can provide real-time in vivo monitoring of the progression of infection. Plain film (x-ray) radiography and CT have been useful for clinical assessments of K. pneumoniae infection severity but are limited by characterizing only anatomic changes in the lung parenchyma, such as ground-glass opacity and consolidations (5) . In contrast, PET imaging with 18 F-FDG has proven useful for imaging inflammation and infection, but 18 F-FDG uptake is not specific and accumulates strongly at sites with increased glucose metabolism such as inflammatory lesions, brain, kidneys, and urinary tract. Furthermore, 18 F-FDG cannot distinguish infections from other conditions such as cancer and inflammation, making it nonspecific for bacterial imaging (6) (7) (8) . Therefore, there is a need for rapid whole-body imaging techniques that can localize a pathogen with specificity and provide a quantitative readout of disease-burden response to treatment.
Besides the lack of specific probes for bacterial infection, another major limitation preventing the effective treatment of bacterial infections is the inability to image them in vivo with the appropriate accuracy and sensitivity. Currently, most imaging agents can detect a high burden of bacteria only in vivo (.10 9 ) (9). Consequently, bacterial infections can be diagnosed only after they have become systemic or have caused significant anatomic tissue damage, a stage at which they are challenging to treat because of the high bacterial burden (.8.3 log10 colony-forming units [CFUs]/mL) (10) . Therefore, there is a great need to develop imaging agents with high selectivity and sensitivity.
Sorbitol, known as a "sugar-free" sweetener, is a metabolic substrate for Enterobacteriaceae. 2-18 F-fluorodeoxysorbitol ( 18 F-FDS), a positron-emitting analog of sorbitol, was first prepared by Li et al. for tumor imaging but was found not to accumulate in cancer cells in vitro (300-fold lower accumulation than that of 18 F-FDG) (11) . A recent study indicated that 18 F-FDS specifically accumulates in several strains of gram-negative bacteria but not gram-positive bacteria, with 1,000-fold higher uptake in Escherichia coli than in mammalian cells. PET/CT imaging results showed that 18 F-FDS accumulated in the thigh of a mouse infected with live E. coli but not in one treated with dead E. coli, whereas there was no significant difference in 18 F-FDG uptake between the two thighs, indicating the high selectivity of 18 F-FDS (12) . Thus 18 F-FDS is a promising PET radiotracer for imaging bacterial infection.
In our current study, we used 18 F-FDS to image mouse lung infection caused by K. pneumoniae. Our objectives were 3-fold: first, to demonstrate that 18 F-FDS can be used as an imaging biomarker to monitor disease progression caused by K. pneumoniae bacterial infection in a mouse lung infection model; second, to demonstrate that 18 F-FDS, in comparison with 18 F-FDG, is a pathogen-specific marker with high specificity in distinguishing bacterial infection caused by K. pneumoniae from sterile lung inflammation; and third, to validate that 18 F-FDS is a potential radiopharmaceutical for imaging bacterial infection by correlating its uptake to bacterial growth measured by bioluminescent imaging (BLI).
MATERIALS AND METHODS
Unless noted otherwise, all chemicals were of analytic grade and purchased from Sigma-Aldrich. 18 F-FDG was purchased from PETNET Solutions Inc. The K. pneumoniae strain (ATCC 43816) was kindly provided by Virginia Miller, of the University of North Carolina at Chapel Hill. 18 F-FDS was prepared from commercially available 18 F-FDG using a published method (12) . Briefly, 18 F-FDG was mixed with 5 mg of solid sodium borohydride at 35°C for 15 min and then quenched with acetic acid, after which the pH was adjusted to 7.4 with sodium bicarbonate. The product was collected by passage through a Sep-Pak Alumina N cartridge (Waters) and 0.2-mm filter. Radiochemical purity was verified by thin-layer chromatography.
Bacterial Uptake Assays
The bioluminescent K. pneumoniae strains (JSKP001 strains), which were created by the insertion of a lux operon between fusA and yeeF genes using 2-stage allelic exchange mutagenesis as described previously (1), were cultured routinely in LB broth (Lennox) agar plates at 37°C. K. pneumoniae was subcultured overnight for 3 h at 37°C. CFUs were enumerated by dilution and plated onto solidified LB broth (Lennox) medium (1) . Radiotracer uptake assays were performed by incubating different numbers of bacterial cultures (10 4 -10 9 bacterial CFUs in 10-fold increments, n 5 6 each) with either 18 F-FDS (20 kBq/mL) or 18 F-FDG at 37°C for 2 h. As a control, heat-killed (90°C for 30 min) bacteria were similarly incubated with each radiotracer. Bacteria were pelleted by centrifugation and washed twice with phosphate buffer, and radioactivity was counted using an automated g-counter. Percentage uptake in bacteria was calculated by 100 · (counts in pellet/total counts).
Animal Models
Murine infection studies were approved by the University of Louisville Institutional Animal Care and Use Committee in accordance with the National Institutes of Health guidelines. Female C57 BL mice (8-10 wk old; Charles River) were inoculated with live K. pneumoniae (10 5 CFUs/mL) or dead K. pneumoniae (10 8 CFUs/mL) using a previously published intubation-mediated intratracheal instillation method (13) .
BLI
For mice infected with live bacteria, BLI was performed using Photon Imager (BioSpace) at 4 different time points: baseline control before inoculation and days 1, 2, and 3 after inoculation. In preparation for in vivo imaging, the mice were anesthetized with 2%-3% isoflurane in an oxygen-filled induction chamber. Once anesthetized, the mice were placed in an imaging chamber connected to an anesthesia delivery system and kept at 1%-2% isoflurane. Images were acquired according to the manufacturer's instructions. The ex vivo BLI images of the major organs were acquired immediately after euthanasia before g-counting. In vivo BLI signals were quantified from a selected region of interest (ROI) and expressed as ph/s. The in vivo lung BLI ROI was used to evaluate the degree of infection.
PET/CT Imaging in Mice with Infection
Twelve mice were imaged by PET/CT on days 1, 2, and 3 after inoculation to monitor disease progression (n 5 12 for each tracer: 18 F-FDS or 18 F-FDG). A 7.4-MBq dose of a radiotracer ( 18 F-FDS or 18 F-FDG) was injected intravenously into each mouse via the tail vein. The mice were then anesthetized with 1.5% isoflurane and placed at the center of the field of view. PET imaging was performed 1 h after inoculation using a microPET-R4 scanner (Siemens) and then followed by CT (microCAT-II; Siemens). Images were reconstructed using an ordered-subsets expectation-maximum algorithm. ROIs were expressed as percentage injected dose (%ID)/g. CT imaging was performed for 10 min immediately after PET imaging for anatomic coregistration and attenuation correction. Nine of the 12 mice were sacrificed immediately after imaging, and then tissues and organs of interest were removed, weighed, and counted. After ex vivo BLI and radioactivity counting, lung tissues were collected for CFU counting. Briefly, the tissues were weighed and homogenized in 1 mL of phosphate-buffered saline, and the cells are lysed with 1% Triton X-100 (The Dow Chemical Company). The diluted samples were quantified after overnight incubation at room temperature. The total CFUs per tissue were estimated using the tissue weight and density.
For another group of 12 mice, PET/CT imaging was performed only when the mice had a fully developed lung infection, as determined by a lung BLI ROI of more than 10 8 . The mice were then immediately sacrificed after imaging (n 5 9). All other procedures were the same as described above.
PET/CT Imaging in Mice with Inflammation
For mice with lung inflammation (n 5 5 for each tracer: 18 F-FDS or 18 F-FDG), PET/CT imaging was performed using a procedure similar to that for the infected group, except that one more time point-day 4 after inoculation-was added.
Statistical Analyses
Statistical comparisons were performed using a 2-tailed Mann-Whitney U or Kruskal-Wallis (for multiple comparisons) test (GraphPad Software Inc.). A P value of less than 0.05 was considered statistically significant.
RESULTS

Bacterial Uptake Assays
Uptake of 18 F-FDS and 18 F-FDG was proportional to the number of bacteria in vitro, reaching a plateau at about 10 8 CFUs/mL. Both radiotracers could detect as few as 10 6 CFUs/mL in vitro. Neither 18 F-FDS nor 18 F-FDG accumulated in dead bacteria (Fig. 1) .
In vitro BLI showed that light intensity was proportional to the number of live bacteria, but no light was detected for dead bacteria.
BLI and PET/CT Imaging in Mice with Infection
For mice that could survive 3 d after inoculation, disease progression was monitored over the time course. Both BLI and PET imaging revealed the increase in lung infection over time (Fig. 2) . BLI detected noticeable lung infection on day 2 after inoculation and significantly greater infection on day 3. Baseline imaging before inoculation showed no focal areas of lung consolidation on CT and low uptake in the lung for both 18 F-FDS and 18 F-FDG. On day 2, an area of lung consolidation was identified on CT, with a corresponding 2.5-fold increase over baseline for both PET radiotracers. On day 3, widespread areas of patchy lung consolidation were observed on CT, with a drastic increase in uptake for 18 F-FDS and 18 F-FDG (9.2-and 3.9-fold, respectively). These results indicated that the uptake of both radiotracers is proportional to bacterial growth.
On the basis of quantification of lung tissue, correlations among BLI, CFUs, and PET were calculated. The correlation equation between lung BLI and CFUs was y 5 0.91x 20.20 18 F-FDS and 18 F-FDG, respectively (y: tracer uptake in lung with unit of % ID/g; x: bioluminescence intensity in lung with unit of log ph/s). 18 F-FDS correlated better with BLI than did 18 F-FDG, indicating a better correlation with CFUs. On the basis of day 2 PET imaging, the minimum CFUs that 18 F-FDS and 18 F-FDG could detect in vivo was 10 7.1 and 10 7.8 , respectively.
The results of the biodistribution studies for 18 F-FDS and 18 F-FDG are shown in Figure 4 . Radioactivity localized mainly in kidney and lung for 18 F-FDS but in brain, heart, spleen, and lung for 18 F-FDG. Uptake in lung was 4.44 6 1.95 and 9.95 6 1.93 %ID/g for 18 F-FDS and 18 F-FDG, respectively. The infected lung-to-heart ratio was 1.6 and 0.7 for 18 F-FDS and 18 F-FDG, respectivelyvalues that were similar to those obtained by PET ROI analysis. Ex vivo BLI for major organs (Fig. 4) found the highest bacterial accumulation to be in lung, with 50-fold lower uptake in liver.
PET/CT Imaging with 18 F-FDS and 18 F-FDG in Mice with Inflammation
For imaging with 18 F-FDG, CT images showed clear inflammation on days 2 and 3, with correspondingly high 18 F-FDG uptake on PET. On day 4, the degree of inflammation was reduced, as inferred by a decrease in 18 F-FDG uptake (Fig. 5A ). For imaging with 18 F-FDS, CT images also showed noticeable inflammation, especially on day 3, but no significant uptake on PET was detected on any day (Fig. 5B) . PET quantification showed that the uptake ratio for infected lung-to-inflamed lung on day 3 was 1.7 and 8.5 for 18 F-FDG and 18 F-FDS, respectively.
DISCUSSION
Enterobacteriaceae rank seventh among the 10 most common pathogens and third among the most common gram-negative pathogens causing device-associated and procedure-associated health care-associated infections (2) . The rising resistance of K. pneumoniae infections to multiple antibiotics, making the treatment challenging, has emerged as a major concern in hospitals, nursing homes, and other health care settings (13) . Therefore, early diagnosis of these infections is critical. In addition, tracking resistant bacteria such as K. pneumoniae is 1 of 4 core actions that will help fight these deadly infections and promote the development of new antibiotics and new diagnostic tests for resistant bacteria (14) .
However, it is challenging to diagnose K. pneumoniae infections at an early stage, because the symptoms look identical to those of a variety of other illnesses, such as cancer and inflammation (15) . Furthermore, discrimination of generalized inflammation from infection is not easy, primarily because of similarities in immune response generated by tissue damage or chronic insult. The currently used imaging techniques are not specific to bacteria but rely largely on the detection of inflammation associated with infection (16) . Thus, it is extremely important to develop an imaging approach capable of discriminating bacterial infection from inflammation and other diseases. Noninvasive imaging can provide realtime in vivo monitoring of the progression of infection that may give insight into the mechanisms that modulate disease progression. PET is a highly sensitive (pmol/L) technique that can be used to detect the presence of specific target molecules in sites of interest. There is still a shortage of effective bacterial infection-specific imaging approaches such as antibodies, antimicrobial peptides, and antibiotics and small molecules (e.g., zinc(II)-dipicolylamine derivatives and the thymidine kinase substrate 1-(2-deoxy-2-fluoro-b-D-arabinofuranosyl)-5-iodoracil) (17) (18) (19) (20) ). 18 F-FDS has been shown not only to differentiate bacterial infection from sterile inflammation but also to discriminate gram-negative bacteria from gram-positive pathogens, cancer cells, and mammalian cells (12) . Moreover, a recent study on healthy volunteers using 18 F-FDS did not detect adverse effects, holding potential for clinical application (21) . In our study, we used 18 F-FDS to image lung infection in mice induced with K. pneumoniae, which was engineered to emit bioluminescent light without the use of exogenous luciferin. For the first time, to our knowledge, we showed the feasibility of using in vivo BLI and 18 F-FDS PET/CT to track the progression of K. pneumoniae infection over time. We also demonstrated that 18 F-FDS was more specific than 18 F-FDG in differentiating K. pneumoniae infection from sterile lung inflammation. To determine the detection threshold for 18 F-FDG and 18 F-FDS in vitro, we performed in vitro tracer uptake experiments using different bacterial loads (live bacteria vs. heat-killed dead bacteria). As shown in Figure 1 , 18 F-FDS could detect as few as 10 6 bacteria in vitro, and 18 F-FDG showed a similar detection sensitivity.
We performed in vivo BLI and PET/CT imaging on mice to assess the potential of 18 F-FDS to be an imaging biomarker to monitor the progression of lung infection. Over the time course of infection, in vivo BLI showed that light intensity increased in the lungs, indicating the development of lung infection due to bacterial dissemination over time. At day 1 after inoculation, there was no bioluminescence signal in the lung, despite the presence of approximately 10 6 bacteria. This should be related to a threshold detection limit of BLI in vivo. By day 2, the bioluminescence signal and tracer accumulation in the lung were clearly visible, and they increased significantly by day 3 (Fig. 2) , indicating that 18 F-FDS might be a suitable radiopharmaceutical for monitoring the progression of bacterial infection. The preliminary data using BLI screening suggested a survival rate of 50% throughout 3 d after inoculation. Our original goal was to have at least 5 mice on day 3 after inoculation; for each radiotracer, we started with 12 mice on day 1 after inoculation, lost about 10%-20% of the mice on day 2, and were left with only 3 mice on day 3. We later noticed that the cumulative stress as the result of frequent tail vein injections, anesthesia during PET/CT scans, and bacterial infection was likely the contributing factor to the overall survival rate of the infected mice. Furthermore, the response of the mice to lung infection varied. A severe infection developed by day 2 in some mice but not until day 3 in most mice. Thus, we used BLI as a screening tool to select mice with adequate lung infection (lung BLI ROIs . 10 8 ph/s) for PET/CT imaging. Immediately after imaging, the mice were sacrificed for biodistribution measurement. This strategy greatly increased the number of mice with lung infection for PET/CT imaging.
Light intensity measured by BLI showed an excellent correlation with CFUs, or bacterial growth (r 5 0.95). Although 18 F-FDS and 18 F-FDG uptake correlated well with BLI and CFUs, 18 F-FDS/PET correlated better with BLI than did 18 F-FDG/PET (r 5 0.85 vs. 0.63), indicating that 18 F-FDS might be better than 18 F-FDG as an imaging biomarker to track bacterial growth.
After imaging, the mice were sacrificed for ex vivo BLI and biodistribution studies to confirm the relationship between uptake and bacterial infection in different organs. Ex vivo BLI detected bacterial accumulation predominantly in lung (.10 8 ph/s) and slightly in heart and liver (;10 6 ) (Fig. 4) . Subsequently, the biodistribution for both radiotracers also showed high lung uptake. For 18 F-FDG, high uptake was also seen in brain, heart, and spleen, indicating the nonspecificity of this radiotracer. 18 F-FDG commonly showed high uptake in brain and heart in mice (22) , and high spleen uptake was probably due to an inflammatory host response to bacteria (23) . The uptake pattern of 18 F-FDS was more specific than that of 18 F-FDG. Lung had the highest uptake, in addition to kidney and blood. High kidney uptake was mostly due to the clearance pathway of 18 F-FDS but not bacterial uptake. A long residence time of 18 F-FDS in the blood implies that 18 F-FDS might require a waiting period, but the advantage of late imaging will decrease if uptake in the lung is diminished. Additionally, we found that uptake in major organs varied greatly among mice with different levels of infection. For healthy mice or mice with mild infection (lung BLI ROIs: 10 4 -10 6 ph/s), more than 90% of 18 F-FDS was cleared from all major organs at 2 h after inoculation, with the blood level reaching as low as 0.08 %ID/g. Although further investigation is warranted, a high lung-tobaseline ratio of 9.3 based on PET imaging (Fig. 2) and a high lung-tomuscle ratio of 3.7 based on biodistribution studies (Fig. 4) suggest that 18 F-FDS imaging at 1 h after radiotracer administration might be sufficient for imaging bacterial infection. Moreover, the biodistribution data from Figure 4 demonstrate much lower uptake of 18 F-FDS in heart, with a lung-to-heart ratio of 1.6 instead of 0.7, compared with 18 F-FDG.
To determine whether 18 F-FDS is more specific than 18 F-FDG in differentiating lung infection from lung inflammation, we performed in vivo BLI and PET/CT imaging using these two radiotracers in mice infected with K. pneumoniae in the lung and mice with sterile lung inflammation caused by dead K. pneumoniae. PET quantification (Fig. 5) showed no significant uptake difference between these two groups for 18 F-FDG (P . 0.05) but a significant difference for 18 F-FDS (P , 0.001), as is consistent with the biodistribution data. Histopathologic evaluation of the lungs inoculated with dead bacteria confirmed the presence of the inflammatory cells in both groups of mice. This finding confirms that 18 F-FDS can be used to specifically differentiate bacterial infection from sterile inflammation, an ability that is extremely critical for early and effective treatment in the clinic. Our findings are consistent with those of a published study (12) that also used 18 F-FDS to image lung infection caused by K. pneumoniae, but the strain of bacteria used in that study was the ATCC 700721 strain, better known as MGH 78578, which is relatively avirulent and has a 50% lethal dose of 10 8 CFUs (23) . In contrast, we used a highly virulent strain (50% lethal dose, 100 CFUs) called ATCC 43816 (13) . This difference explains why the animals in the other study were inoculated with a higher dose of bacteria but developed only mild lung infection on day 5 after inoculation whereas our animals started to develop lung infection on day 2, with a mortality rate of about 10%-20%, and infection was fully developed on day 3, with a survival rate of 30%-40%. This finding further highlights the importance of early and effective diagnosis of this type of infection with such a high mortality rate. It is worth noting that the K. pneumoniae bacteria used in our study were engineered to emit light, and it was thus possible to use bioluminescence imaging to follow bacterial growth in vivo.
CONCLUSION
The degree of lung infection measured by BLI correlated better with 18 F-FDS uptake than with 18 F-FDG uptake. Both 18 F-FDS and 18 F-FDG showed a reasonable detection threshold for imaging bacterial infection. 18 F-FDS was more specific than 18 F-FDG in differentiating K. pneumoniae lung infection from lung inflammation. Therefore, 18 F-FDS can be considered a promising imaging biomarker for early diagnosis of K. pneumoniae lung infections in mice. Currently, the imaging modalities used to investigate patients carrying or suspected of having lung infection are chest radiography and CT, but CT is much more sensitive and specific than chest radiography. However, the interpretation of CT images for lung disorders can be complex if the differential diagnosis needs to distinguish between inflammation and infection. Thus, 18 F-FDS PET/CT can be used initially for follow-up after an inconclusive CT diagnosis for suspected lung infection. As proven clinical data accumulate over time, 18 F-FDS PET/CT can potentially become a new clinical standard for confirming lung infection.
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